Artelo Biosciences, Inc. (ARTL )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ARTL
- Company Artelo Biosciences, Inc.
- Price $0.95
- Changes Percentage 0.11
- Change 0.001
- Day Low $0.95
- Day High $0.99
- Year High $1.7
- Year Low $0.91
- Market Cap $3,120,260
- Price Avg 50 EMA (D) $1.15
- Price Avg 200 EMA (D) $1.2
- Exchange NASDAQ
- Volume 7,716
- Average Volume 27,837
- Open $0.95
- Previous Close $0.95
- EPS -3.05
- PE -0.31
- Earnings Announcement 2025-05-12 12:30:00
- Shares Outstanding $3,281,030
Company brief: ARTELO BIOSCIENCES, INC. (ARTL )
- Healthcare
- Biotechnology
- Mr. Gregory D. Gorgas M.B.A.
- https://www.artelobio.com
- US
- N/A
- 06-21-2019
- US04301G5080
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.